Skip Navigation
Skip to contents

J Pathol Transl Med : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
3 "Boram Song"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Intraosseous Hibernoma: A Rare and Unique Intraosseous Lesion
Boram Song, Hye Jin Ryu, Cheol Lee, Kyung Chul Moon
J Pathol Transl Med. 2017;51(5):499-504.   Published online August 22, 2017
DOI: https://doi.org/10.4132/jptm.2017.07.28
  • 8,130 View
  • 128 Download
  • 11 Web of Science
  • 16 Crossref
AbstractAbstract PDF
Background
Hibernoma is a rare benign tumor of adults that is composed of multivacuolated adipocytes resembling brown fat cells. Hibernoma typically occurs in soft tissue, and intraosseous examples are very rare. Intraosseous hibernomas can radiologically mimic metastatic carcinoma and other tumorous conditions. Methods: To collect the intraosseous hibernomas, we searched the pathologic database and reviewed the hematoxylin and eosin (H&E)–stained slides of bone biopsy samples performed to differentiate radiologically abnormal bone lesions from 2006 to 2016. A total of six intraosseous hibernoma cases were collected, and clinical and radiological information was verified from electronic medical records. H&E slide review and immunohistochemical staining for CD68, pan-cytokeratin, and S-100 protein were performed. Results: Magnetic resonance imaging of intraosseous hibernomas showed low signal intensity with slightly hyperintense foci on T1 and intermediate to high signal intensity on T2 weighted images. Intraosseous hibernomas appeared as heterogeneous sclerotic lesions with trabecular thickening on computed tomography scans and revealed mild hypermetabolism on positron emission tomography scans. Histopathologically, the bone marrow space was replaced by sheets of multivacuolated, foamy adipocytes resembling brown fat cells, without destruction of bone trabeculae. In immunohistochemical analysis, the tumor cells were negative for CD68 and pan-cytokeratin and positive for S-100 protein. Conclusions: Intraosseous hibernoma is very rare. This tumor can be overlooked due to its rarity and resemblance to bone marrow fat. Pathologists need to be aware of this entity to avoid misdiagnosis of this rare lesion.

Citations

Citations to this article as recorded by  
  • A Rare Case of Large Lateral Chest Wall Hibernoma
    Lyubomir Gaydarski, Boycho Landzhov, Ivaylo Kamenov, Julian M Ananiev, Georgi P Georgiev
    Cureus.2024;[Epub]     CrossRef
  • Intraosseous hibernoma mimicking sclerotic bone metastasis—a case report
    Ali Shaikh, Adil Basha, George Ray, Justin A. Bishop, Avneesh Chhabra
    Skeletal Radiology.2024;[Epub]     CrossRef
  • Femoral hibernoma: unique intraosseous tumor
    Gökhan Tonkaz, Ertugrul Cakir, Mehmet Tonkaz, Demet Sengul
    Wiener klinische Wochenschrift.2024; 136(19-20): 581.     CrossRef
  • Unusual Imaging Findings of Epithelioid Hemangioma: Case Report of Single Intramedullary Sclerotic Bone Lesion
    Yun Chul Hwang, Tae Eun Kim, Jae Hyuck Yi
    Journal of the Korean Society of Radiology.2024; 85(5): 986.     CrossRef
  • Benign incidental do-not-touch bone lesions
    Nuttaya Pattamapaspong, Wilfred CG Peh
    The British Journal of Radiology.2023;[Epub]     CrossRef
  • Intraosseous hibernoma: clinicopathologic and imaging analysis of 18 cases
    Chiraag N Gangahar, Carina A Dehner, David P Wang, Behrang Amini, Travis Hillen, Christopher O'Conor, Sydney N Jennings, Kathleen Byrnes, Elizabeth A Montgomery, Bogdan A Czerniak, Julia A Bridge, Molly C Schroeder, Jack W Jennings, Wei‐Lien Wang, John S
    Histopathology.2023; 83(1): 40.     CrossRef
  • Intraosseous Hibernoma: A Rare Entity in Orthopedics With Peculiar Radiological Features
    Ramy Samargandi, Louis-Romée Le Nail, Gonzague de Pinieux, Matthias Tallegas, Elodie Miquelestorena-Standley
    Cureus.2023;[Epub]     CrossRef
  • Intraosseous hibernoma of the appendicular skeleton
    Salvatore Gitto, Thom Doeleman, Michiel A. J. van de Sande, Kirsten van Langevelde
    Skeletal Radiology.2022; 51(6): 1325.     CrossRef
  • Intraosseous hibernoma: Two case reports and a review of the literature
    Samantha N. Weiss, Ankit Mohla, Gord Guo Zhu, Christina Gutowski, Tae Won B Kim, Rohan Amin
    Radiology Case Reports.2022; 17(7): 2477.     CrossRef
  • Hibernoma of two contiguous vertebrae: uniqueness of a lesion already rare in itself
    Donato MASTRANTUONO, Domenico MARTORANO, Guido REGIS, Federica ARABIA, Alessandra LINARI, Federica SANTORO
    Journal of Radiological Review.2022;[Epub]     CrossRef
  • Primary extradural tumors of the spinal column
    Varun Arvind, Edin Nevzati, Maged Ghaly, Mansoor Nasim, Mazda Farshad, Roman Guggenberger, Daniel Sciubba, Alexander Spiessberger
    Journal of Craniovertebral Junction and Spine.2021; 12(4): 336.     CrossRef
  • Spinal Intraosseous Hibernoma: A Case Report and Review of Literature
    Mi-Kyung Um, Eugene Lee, Joon Woo Lee, Kyu Sang Lee, Yusuhn Kang, Joong Mo Ahn, Heung Sik Kang
    Journal of the Korean Society of Radiology.2020; 81(4): 965.     CrossRef
  • Intraosseous hibernoma: A metastatic mimicker to consider on the differential
    Allen Ko, Colin C. Rowell, James B. Vogler, Dmitri E. Samoilov
    Radiology Case Reports.2020; 15(12): 2677.     CrossRef
  • Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology
    Yu Jin Kim, Mingi Kim, Hyung Kyu Park, Dan Bi Yu, Kyungsoo Jung, Kyoung Song, Yoon-La Choi
    Laboratory Investigation.2019; 99(9): 1309.     CrossRef
  • Intraosseous Hibernoma: Five Cases and a Review of the Literature
    Francisco A. Myslicki, Andrew E. Rosenberg, Ivan Chaitowitz, Ty K. Subhawong
    Journal of Computer Assisted Tomography.2019; 43(5): 793.     CrossRef
  • Hibernoma Mimicking Atypical Lipomatous Tumor
    Youssef Al Hmada, Inga-Marie Schaefer, Christopher D.M. Fletcher
    American Journal of Surgical Pathology.2018; 42(7): 951.     CrossRef
Implication of PHF2 Expression in Clear Cell Renal Cell Carcinoma
Cheol Lee, Bohyun Kim, Boram Song, Kyung Chul Moon
J Pathol Transl Med. 2017;51(4):359-364.   Published online June 13, 2017
DOI: https://doi.org/10.4132/jptm.2017.03.16
  • 7,138 View
  • 166 Download
  • 9 Web of Science
  • 10 Crossref
AbstractAbstract PDF
Background
Clear cell renal cell carcinoma (CCRCC) is presumed to be associated with adipogenic differentiation. Histone modification is known to be important for adipogenesis, and the function of histone demethylase plant homeodomain finger 2 (PHF2) has been noted. In addition, PHF2 may act as a tumor suppressor via epigenetic regulation of p53 and is reported to be reduced in colon cancer and stomach cancer tissues. In this study, we examined PHF2 expression in CCRCC specimens by immunohistochemistry.
Methods
We studied 254 CCRCCs and 56 non-neoplastic renal tissues from patients who underwent radical or partial nephrectomy between 2000 and 2003 at the Seoul National University Hospital. Tissue microarray blocks were prepared, and immunohistochemical staining for PHF2 was performed.
Results
Among 254 CCRCC cases, 150 cases (59.1%) showed high expression and 104 cases (40.1%) showed low expression. High expression of PHF2 was significantly correlated with a low Fuhrman nuclear grade (p < .001), smaller tumor size (p < .001), low overall stage (p = .003), longer cancer-specific survival (p = .002), and progression-free survival (p < .001) of the patients. However, it was not an independent prognostic factor in multivariate analysis adjusted for Fuhrman nuclear grade and overall stage.
Conclusions
Our study showed that low expression of PHF2 is associated with aggressiveness and poor prognosis of CCRCC.

Citations

Citations to this article as recorded by  
  • The role of histone methylation in renal cell cancer: an update
    Yanguang Hou, Yan Yuan, Yanze Li, Lei Wang, Juncheng Hu, Xiuheng Liu
    Molecular Biology Reports.2023; 50(3): 2735.     CrossRef
  • Phosphorylation of PHF2 by AMPK releases the repressive H3K9me2 and inhibits cancer metastasis
    Ying Dong, Hao Hu, Xuan Zhang, Yunkai Zhang, Xin Sun, Hanlin Wang, Weijuan Kan, Min-jia Tan, Hong Shi, Yi Zang, Jia Li
    Signal Transduction and Targeted Therapy.2023;[Epub]     CrossRef
  • HIF-1α-mediated augmentation of miRNA-18b-5p facilitates proliferation and metastasis in osteosarcoma through attenuation PHF2
    Peng Luo, Yan-dong Zhang, Feng He, Chang-jun Tong, Kai Liu, He Liu, Shi-zhuang Zhu, Jian-zhou Luo, Bing Yuan
    Scientific Reports.2022;[Epub]     CrossRef
  • Integration of meta-analysis and supervised machine learning for pattern recognition in breast cancer using epigenetic data
    Reza Panahi, Esmaeil Ebrahimie, Ali Niazi, Alireza Afsharifar
    Informatics in Medicine Unlocked.2021; 24: 100629.     CrossRef
  • PHF2 regulates homology-directed DNA repair by controlling the resection of DNA double strand breaks
    Ignacio Alonso-de Vega, Maria Cristina Paz-Cabrera, Magdalena B Rother, Wouter W Wiegant, Cintia Checa-Rodríguez, Juan Ramón Hernández-Fernaud, Pablo Huertas, Raimundo Freire, Haico van Attikum, Veronique A J Smits
    Nucleic Acids Research.2020; 48(9): 4915.     CrossRef
  • Emerging of lysine demethylases (KDMs): From pathophysiological insights to novel therapeutic opportunities
    Sarder Arifuzzaman, Mst Reshma Khatun, Rabeya Khatun
    Biomedicine & Pharmacotherapy.2020; 129: 110392.     CrossRef
  • Biology and targeting of the Jumonji-domain histone demethylase family in childhood neoplasia: a preclinical overview
    Tyler S. McCann, Lays M. Sobral, Chelsea Self, Joseph Hsieh, Marybeth Sechler, Paul Jedlicka
    Expert Opinion on Therapeutic Targets.2019; 23(4): 267.     CrossRef
  • MiR-221 Promotes Hepatocellular Carcinoma Cells Migration via Targeting PHF2
    Yi Fu, Mingyan Liu, Fengxia Li, Li Qian, Ping Zhang, Fengwei Lv, Wenting Cheng, Ruixing Hou
    BioMed Research International.2019; 2019: 1.     CrossRef
  • PHF2 histone demethylase prevents DNA damage and genome instability by controlling cell cycle progression of neural progenitors
    Stella Pappa, Natalia Padilla, Simona Iacobucci, Marta Vicioso, Elena Álvarez de la Campa, Claudia Navarro, Elia Marcos, Xavier de la Cruz, Marian A. Martínez-Balbás
    Proceedings of the National Academy of Sciences.2019; 116(39): 19464.     CrossRef
  • Plant homeodomain finger protein 2 as a novel IKAROS target in acute lymphoblastic leukemia
    Zheng Ge, Yan Gu, Qi Han, Justin Sloane, Qinyu Ge, Goufeng Gao, Jinlong Ma, Huihui Song, Jiaojiao Hu, Baoan Chen, Sinisa Dovat, Chunhua Song
    Epigenomics.2018; 10(1): 59.     CrossRef
Article image
Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma
Gilhyang Kim, Yul Ri Chung, Bohyun Kim, Boram Song, Kyung Chul Moon
J Pathol Transl Med. 2016;50(6):436-441.   Published online October 10, 2016
DOI: https://doi.org/10.4132/jptm.2016.07.12
  • 8,268 View
  • 116 Download
  • 4 Web of Science
  • 4 Crossref
AbstractAbstract PDF
Background
Human epidermal growth factor receptor 2 (HER2) is one of the known oncogenes in urothelial carcinoma. However, the association between HER2 and the prognosis of upper urinary tract urothelial carcinoma (UUTUC) has not yet been fully clarified. The aim of this study was to evaluate HER2 expression using the United States Food and Drug Administration (FDA) criteria and American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) criteria and compare their prognostic significance in UUTUC.
Methods
HER2 expression was evaluated in 144 cases of UUTUC by immunohistochemistry (IHC) using tissue microarrays. We separately analyzed HER2 expression using the FDA and ASCO/CAP criteria. The IHC results were categorized into low (0, 1+) and high (2+, 3+) groups.
Results
Using the FDA criteria, 94 cases were negative, 38 cases were 1+, nine cases were 2+, and three cases were 3+. Using the ASCO/CAP criteria, 94 cases were negative, 34 cases were 1+, 13 cases were 2+, and three cases were 3+. Four cases showing 2+ according to the ASCO/CAP criteria were reclassified as 1+ by the FDA criteria. High HER2 expression by both the FDA criteria and ASCO/CAP criteria was significantly associated with International Society of Urological Pathology high grade (p = .001 and p < .001). The high HER2 expression group classified with the FDA criteria showed significantly shorter cancer-specific survival (p = .004), but the HER2 high and low expression groups classified with the ASCO/CAP criteria did not show significant differences (p = .161) in cancer-specific survival.
Conclusions
HER2 high expression groups were significantly associated with shorter cancer-specific survival, and our study revealed that the FDA criteria are more suitable for determining HER2 expression in UUTUC.

Citations

Citations to this article as recorded by  
  • A systematic review and meta-analysis for human epidermal growth factor receptor 2 on upper tract urothelial carcinoma patients
    Jianjun Ye, Xinyang Liao, Yu Qiu, Qiang Wei, Yige Bao
    Tumori Journal.2024; 110(1): 25.     CrossRef
  • ERBB2 Amplification as a Predictive and Prognostic Biomarker in Upper Tract Urothelial Carcinoma
    Annette Zimpfer, Said Kdimati, Melanie Mosig, Henrik Rudolf, Heike Zettl, Andreas Erbersdobler, Oliver W. Hakenberg, Matthias Maruschke, Björn Schneider
    Cancers.2023; 15(9): 2414.     CrossRef
  • Near-Infrared Photoimmunotherapy (NIR-PIT) in Urologic Cancers
    Hiroshi Fukushima, Baris Turkbey, Peter A. Pinto, Aki Furusawa, Peter L. Choyke, Hisataka Kobayashi
    Cancers.2022; 14(12): 2996.     CrossRef
  • Assessment of HER2 Protein Overexpression and Gene Amplification in Renal Collecting Duct Carcinoma: Therapeutic Implication
    Manuela Costantini, Carla Azzurra Amoreo, Liborio Torregrossa, Greta Alì, Enrico Munari, Carmen Jeronimo, Rui Henrique, Sara Petronilho, Umberto Capitanio, Roberta Lucianò, Nazareno Suardi, Maria Teresa Landi, Umberto Anceschi, Aldo Brassetti, Vito Michel
    Cancers.2020; 12(11): 3345.     CrossRef

J Pathol Transl Med : Journal of Pathology and Translational Medicine
TOP